About Agent Capital

Investments That Matter

Agent Capital is a healthcare venture capital firm focused on investing in novel, differentiated therapeutics and treatments that address unmet patient needs.

From preclinical to commercial, we make direct equity investments across all stages of development.

Our team partners with scientists, entrepreneurs and other investors to develop the next generation of healthcare innovations, focusing on making a difference in patients’ lives.

 

Watch Video

Investment Team

Geeta Vemuri, PhD, MBA

Managing Partner

Geeta Vemuri, PhD, MBA

Managing Partner

Prior to Agent Capital, Dr. Vemuri was the Managing Partner of Baxalta Ventures, the corporate venture capital arm of Baxalta, where she led investment decisions for the $200M pool of capital across multiple therapeutic areas of interest to Baxalta. Prior to Baxalta Ventures, Dr. Vemuri established and led Baxter Ventures, which was Baxter’s $200M corporate venture arm. As its Managing Partner, Dr. Vemuri led the investment decisions, including direct equity investments and select fund investments. Prior to Baxter, Dr. Vemuri was a Partner at Quaker Partners where she previously joined as a Senior Associate. While at Quaker, she focused on biotech and healthcare investments. Dr. Vemuri served on the board as voting member or observer across a variety of companies, including Cempra (until its IPO and Dr. Vemuri’s departure in 2011), Covagen (acq. by Janssen), Gadeta BV (until departure from Shire in 2016), Naurex (acq. by Allergan), Ocular Therapeutix, Protez Pharmaceuticals (acq. by Novartis), Syntimmune (until departure from Shire in 2016) and True North Therapeutics (acq. by Bioverativ). Dr. Vemuri received a PhD in biochemistry from Indian Institute of Sciences and an MBA from Wharton School at the University of Pennsylvania.

×

Marta New, PhD, MBA

Partner

Marta New, PhD, MBA

Partner

Prior to Agent Capital, Dr. New was a Principal at Baxalta Ventures, the corporate venture capital arm of Baxalta, where she led venture capital investments and served as a board observer for Gadeta BV, Syntimmune, and Vitesse Biologics. Prior to Baxalta, Dr. New was a Senior Associate at Baxter Ventures, the corporate venture capital arm of Baxter, where she supported scientific diligence, financial modeling, investment closings, and competitive market analyses, and also aided in the formation of academic new company spinouts. Dr. New originally joined Baxter as a Senior Manager in the Global Renal Marketing franchise, where she was a commercial lead for new product development and lifecycle management projects. Dr. New joined Baxter from Northwestern University, Innovation and New Ventures Office and Feinberg School of Medicine where she was a Lead Commercialization Consultant for new company formation, licensing and alliance management. Dr. New received her PhD from the University of Illinois at Chicago in microbiology and immunology and completed her post-doctoral training at Northwestern University. She also received her MBA from Northwestern University Kellogg School of Management.

×

Preston Noon, PharmD, MBA

Principal

Preston Noon, PharmD, MBA

Principal

Prior to Agent Capital, Dr. Noon was a Senior Associate at Baxalta Ventures, the corporate venture capital arm of Baxalta, where he was responsible for supporting new investment opportunities. While at Baxalta, Dr. Noon developed investment memorandums, led diligence teams, modeled exit scenarios, and sourced new investment opportunities. Prior to Baxalta Ventures, Dr. Noon was a post-doctoral Associate for the U.S. Business Development and Licensing group of Bayer Pharmaceuticals, where he worked on in-licensing assets, acquisitions and asset divestitures. Prior to Bayer, Dr. Noon was an MBA analyst at Bristol-Myers Squibb for Global Medical Affairs. He began his career in the pharmaceutical industry working at Bristol-Myers Squibb to support clinical trial operations, specifically to monitor and improve enrollment timelines for oncology and immunology assets, including ipilimumab and nivolumab. Dr. Noon is a Kauffman Fellow, member of Class 23. He received a PharmD and MBA each from the University of Connecticut.

×
×
×

Venture Partners

John Glasspool

Venture Partner

John Glasspool

Venture Partner

John has over 25 years of deep commercial industry expertise, including executive leadership roles at Baxalta, Baxter, and Novartis. Most recently, John was former Executive VP and Head of Corporate Strategy & Commercial Operations at Baxalta. Previously, John was Head of Region Europe, Vaccines and Diagnosis at Novartis, as well as Head of Pricing, Market Access and Commercial Operations.

×

Bruce Peacock

Venture Partner

Bruce Peacock

Venture Partner

Bruce brings over 25 years of industry expertise, most recently as a former Venture Partner at SV Health Investors. He has held numerous senior operating positions including as Executive VP & COO of Cephalon, and Senior VP & CFO of Centocor.

×
×

Industry Advisors

David Meek

Ipsen, CEO & Board Member

David has over 25 years of experience in the pharmaceutical industry where he has held various global executive positions in major pharmaceutical and biotechnology companies. Prior to joining Ipsen David was Executive Vice President and President of the oncology division of Baxalta.

Norbert Riedel, PhD

Aptinyx, President & CEO

Norbert has held multiple executive leadership roles, including as former President and CEO of Naurex (acquired by Allergan), former Corporate Vice President and Chief Science and Innovation Officer of Baxter, and as Head of Worldwide Biotechnology for Hoechst Marion Roussel (now Sanofi).

Wilbur H. Gantz, III

PathoCapital, President

Bill was the former Executive Chairman and CEO of Ovation Pharmaceuticals (acquired by Lundbeck) and former CEO and President of PathoGenesis Corporation. He also held senior executive roles for over 20 years at Baxter International, including as President and as Chief Operating Officer.

Robert L. Parkinson, Jr.

Baxter, Chairman Emeritus

Bob has many decades of executive leadership experience in the pharmaceutical industry. Most recently Bob was named Chairman Emeritus of Baxter International, where he was previously the Chief Executive Officer, President and Chairman of Baxter Healthcare Corporation from 2004 to 2016.

Ivana Magovčević-Liebisch, Ph.D, J.D

Ipsen, Chief Business Officer & Executive VP

Ivana has over 20 years experience in the pharmaceutical industry, including deep business development expertise. Prior to joining Ipsen, Ivana was Executive VP and Chief Strategy & Corporate Development Officer at Axcella Health, and Senior Vice President and Head of Global Business Development for specialty drugs at Teva Pharmaceuticals.

Alicia Löffler

Northwestern Univ., Associate Provost

Alicia is the Associate Provost for Innovation & New Ventures, Associate Vice President for Research, and Executive Director for Innovation and New Ventures Office for Northwestern University, overseeing all start-up and commercialization efforts at the university.

Gwen Melincoff

Agent Capital, Business Development Advisor

Gwen has over 25 years of leadership in the biotechnology and pharmaceutical industries. She has extensive business and board experience in major pharmaceutical and biotech companies as well as medical devices. Currently she serves on the board of Collegium Pharmaceutical, among others.